A Phase 1 interventional study of Necitumumab and Abemaciclib in Carcinoma, Non-Small-Cell Lung and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung — none open to participants now, 2 under way, none of them phase 3. necitumumab · Carcinoma, Non-Small-Cell Lung.
Among the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 5 in phase 1, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
necitumumab: first FDA approval 2015 (PORTRAZZA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 2
First in 2009; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 13 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 4 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 90th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2015, is one of 28 in phase 1, and was the 108th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing necitumumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT02496663National Cancer Institute (NCI)Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is medical research evaluating the safety and efficacy of two new medicines (necitumumab and abemaciclib), administered in combination in participants affected by a defined type of advanced lung cancer (stage IV non-small-cell lung cancer).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed NSCLC Stage IV:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met. Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met. Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met. Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.
Drug: Necitumumab · Drug: Abemaciclib
Administered IV.
Also known as: LY3012211
Administered orally.
Also known as: LY2835219
Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)
A DLT was defined as one of the following adverse events (AEs), occurring in Cycle 1 if considered to be definitely, probably, or possibly related to necitumumab and abemaciclib: Grade 3 or 4 nonhematologic toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0), except for nausea, vomiting, diarrhea, or electrolyte disturbance. Grade 3 or 4 nausea, vomiting, or diarrhea that persists more than 2 days despite maximal supportive intervention. Grade 3 thrombocytopenia with bleeding requiring transfusion. Grade 4 thrombocytopenia with or without bleeding. Grade 4 neutropenia that persists more than 5 days.
Time frame: Baseline through Cycle 1 (Up to 21 Days)
Progression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months)
PFS is defined as the time from baseline until first observation of progressive disease(PD) defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause.PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 millimeter (mm) or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization, regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis, the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.
Time frame: Baseline to measured progressive disease or death due to any cause (3 Months)
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete or Partial Response (Objective Response Rate [ORR])
ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Confidence intervals are based on Clopper-Pearson method.
Time frame: Baseline to measured progressive disease or start of new anti-cancer therapy (up to 21 months)
Pharmacokinetics (PK): Predose Concentration (Cmin) of Necitumumab
Predose necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.
Time frame: Cycle 1, Day 8 (C1D8) and C2,3,5,7 D1: Predose
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab
Maximum necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.
Time frame: Cycle 1, Day 1 (C1D1): 0.25, 2,4,10 hours(h) post dose, C1D8: 0.25h post dose, Cycle 2, Day 1 (C2D1): 0.25, 2,4,10h post dose; C3,5,7 D1: 0.25h post dose
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib.
Time frame: Cycle 1, Day 1 (C1D1): 0.25, 2,4,6,8,10 hours(h) post dose, C1D8: 0.25h post dose, C2D1: 0.25, 2,4,6,8,10h post dose; C3,5,7 D1: 0.25h post dose
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC[0-tlast]) Abemaciclib
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC\[0-tlast\]) summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib. (tlast = 10 hours)
Time frame: Cycle 1, Day 1 (C1D1): 0.25, 2,4,6,8,10 hours(h) post dose
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])
Disease Control Rate (DCR) is defined as the percentage of participants achieving a best overall response of stable disease (SD), PR, or CR. DCR used the same denominator as defined in ORR. Among participants counted in the denominator, the numerator counted those with a confirmed best tumor response of SD, PR, or CR per RECIST v1.1. Confidence intervals are based on Clopper-Pearson method.
Time frame: Baseline to measured progressive disease or start of new anti-cancer therapy (up to 21 months)
Overall Survival
Overall survival (OS) is defined as the time from the date of study enrollment to the date of death from any cause. For each participant who is not known to have died as of the data -inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date.
Time frame: Baseline to date of death from any cause (24 Months)
| Milestone | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) |
|---|---|---|---|
| Started | 3 | 57 | 6 |
| Part a | 3 | 6 | 6 |
| Expansion cohort part b | 0 | 51 | 0 |
| Progressive disease | 3 | 42 | 3 |
| Death | 0 | 2 | 0 |
| Completed | 3 | 47 | 3 |
| Not completed | 0 | 10 | 3 |
| Withdrew: Adverse event | 0 | 4 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 |
| Withdrew: Physician decision | 0 | 3 | 1 |
A DLT was defined as one of the following adverse events (AEs), occurring in Cycle 1 if considered to be definitely, probably, or possibly related to necitumumab and abemaciclib: Grade 3 or 4 nonhematologic toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0), except for nausea, vomiting, diarrhea, or electrolyte disturbance. Grade 3 or 4 nausea, vomiting, or diarrhea that persists more than 2 days despite maximal supportive intervention. Grade 3 thrombocytopenia with bleeding requiring transfusion. Grade 4 thrombocytopenia with or without bleeding. Grade 4 neutropenia that persists more than 5 days.
| Participants | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumamab 800 mg + Abemaciclib 200 mg) |
|---|---|---|---|
| Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs) | 0 | 1 | 3 |
PFS is defined as the time from baseline until first observation of progressive disease(PD) defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause.PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 millimeter (mm) or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization, regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis, the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.
| percentage of participants | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) |
|---|---|---|---|
| Progression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months) | 66.7 (5.4 to 94.5) | 32.3 (20.4 to 44.8) | 50.0 (11.1 to 80.4) |
ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Confidence intervals are based on Clopper-Pearson method.
| percentage of participants | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total Enrolled Participants (Necitumumab + Abemaciclib) |
|---|---|---|---|---|
| Overall Response Rate | 66.7 (9.4 to 99.2) | 5.3 (1.1 to 14.6) | 0.0 (0.0 to 45.9) | 7.6 (2.5 to 16.8) |
| PR | 66.7 (9.4 to 99.2) | 5.3 (1.1 to 14.6) | 0.0 (0.0 to 45.9) | 7.6 (2.5 to 16.8) |
| SD | 33.3 (0.8 to 90.6) | 42.1 (29.1 to 55.9) | 66.7 (22.3 to 95.7) | 43.9 (31.7 to 56.7) |
| PD | 0.0 (0.0 to 70.8) | 47.4 (34.0 to 61.0) | 16.7 (0.4 to 64.1) | 42.4 (30.3 to 55.2) |
Predose necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.
| microgram/milliliter (μg/mL) | Necitumumab |
|---|---|
| Cycle 1, Day 8 | 64.1 ± 43.1 |
| Cycle 2, Day 1 | 49.6 ± 63.8 |
| Cycle 3, Day 1 | 93.8 ± 44.1 |
| Cycle 5, Day 1 | 160 ± 50.3 |
| Cycle 7, Day 1 | 165 ± 42.1 |
Maximum necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.
| μg/mL | Necitumumab |
|---|---|
| Cycle 1, Day 1 | 228 ± 45.6 |
| Cycle 1, Day 8 (D8) | 304 ± 21.9 |
| Cycle 2, Day 1 | 270 ± 25.6 |
| Cycle 3, Day 1 | 318 ± 43.7 |
| Cycle 5, Day 1 | 356 ± 42.7 |
| Cycle 7, Day 1 | 350 ± 24.7 |
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib.
| nanogram/milliliter (ng/mL) | Abemaciclib 100 mg | Abemaciclib 150 mg | Abemaciclib 200 mg |
|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib | 15.6 ± 146 | 26 ± 148 | 38.2 ± 80 |
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC\[0-tlast\]) summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib. (tlast = 10 hours)
| hour*nanogram/milliliter (hr*ng/mL) | Abemaciclib 100 mg | Abemaciclib 150 mg | Abemaciclib 200 mg |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC[0-tlast]) Abemaciclib | 118 ± 200 | 209 ± 136 | 336 ± 83 |
Disease Control Rate (DCR) is defined as the percentage of participants achieving a best overall response of stable disease (SD), PR, or CR. DCR used the same denominator as defined in ORR. Among participants counted in the denominator, the numerator counted those with a confirmed best tumor response of SD, PR, or CR per RECIST v1.1. Confidence intervals are based on Clopper-Pearson method.
| percentage of participants | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total Enrolled Participants (Necitumumab + Abemaciclib) |
|---|---|---|---|---|
| Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR]) | 100 (29.2 to 100.0) | 47.4 (34.0 to 61.0) | 66.7 (22.3 to 95.7) | 51.5 (38.9 to 64.0) |
Overall survival (OS) is defined as the time from the date of study enrollment to the date of death from any cause. For each participant who is not known to have died as of the data -inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date.
| Months | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) |
|---|---|---|---|
| Overall Survival | NA (18.20 to NA) | 6.93 (4.96 to 12.85) | 13.45 (1.31 to 18.53) |
Collected over Up to 21 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Necitumumab 800 mg + Abemaciclib 100 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Necitumumab 800 mg + Abemaciclib 150 mg | 5/57 (8.8%) | 25/57 (43.9%) | 57/57 (100%) |
| Necitumumab 800 mg + Abemaciclib 200 mg | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Event | Necitumumab 800 mg + Abemaciclib 100 mg | Necitumumab 800 mg + Abemaciclib 150 mg | Necitumumab 800 mg + Abemaciclib 200 mg |
|---|---|---|---|
| CholecystitisHepatobiliary disorders | 1/3 | 0/57 | 0/6 |
| Respiratory tract infectionInfections and infestations | 1/3 | 0/57 | 0/6 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/3 | 0/57 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/57 | 1/6 |
| PyrexiaGeneral disorders | 0/3 | 2/57 | 1/6 |
| Anal abscessInfections and infestations | 0/3 | 0/57 | 1/6 |
| HydronephrosisRenal and urinary disorders | 0/3 | 0/57 | 1/6 |
| UreterolithiasisRenal and urinary disorders | 0/3 | 0/57 | 1/6 |
| VomitingGastrointestinal disorders | 0/3 | 5/57 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 2/57 | 0/6 |
| Event | Necitumumab 800 mg + Abemaciclib 100 mg | Necitumumab 800 mg + Abemaciclib 150 mg | Necitumumab 800 mg + Abemaciclib 200 mg |
|---|---|---|---|
| FatigueGeneral disorders | 2/3 | 29/57 | 3/6 |
| PyrexiaGeneral disorders | 2/3 | 10/57 | 2/6 |
| ParonychiaInfections and infestations | 2/3 | 6/57 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 21/57 | 4/6 |
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 12/57 | 4/6 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 2/3 | 26/57 | 3/6 |
| Dry skinSkin and subcutaneous tissue disorders | 2/3 | 15/57 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 29/57 | 3/6 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 21/57 | 3/6 |
| NauseaGastrointestinal disorders | 0/3 | 24/57 | 3/6 |
All enrolled participants who received at least one dose of study drug. Cohort 2 includes total number of participants in Part A and evaluable participants of Part B.
| Age, Continuous(years) | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total |
|---|---|---|---|---|
| Mean | 62.33 ± 2.31 | 61.42 ± 10.58 | 49.00 ± 7.59 | 60.33 ± 10.68 |
| Sex: Female, Male(Participants) | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total |
|---|---|---|---|---|
| Female | 1 | 17 | 1 | 19 |
| Male | 2 | 40 | 5 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 2 |
| Not Hispanic or Latino | 1 | 13 | 1 | 15 |
| Unknown or Not Reported | 2 | 42 | 5 | 49 |
| Race (NIH/OMB)(Participants) | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 1 | 16 | 1 | 18 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 41 | 5 | 48 |
| Region of Enrollment(Participants) | Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg) | Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg) | Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg) | Total |
|---|---|---|---|---|
| Belgium | 1 | 9 | 1 | 11 |
| France | 2 | 45 | 5 | 52 |
| Spain | 0 | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Jun 2017, 24 months.
Results were first posted in Jul 2020, 3 years after primary completion.
Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 24 months is below that.
Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Necitumumab · Abemaciclib
Carcinoma, Non-Small-Cell Lung →